CL2015002060A1 - Compuestos. - Google Patents

Compuestos.

Info

Publication number
CL2015002060A1
CL2015002060A1 CL2015002060A CL2015002060A CL2015002060A1 CL 2015002060 A1 CL2015002060 A1 CL 2015002060A1 CL 2015002060 A CL2015002060 A CL 2015002060A CL 2015002060 A CL2015002060 A CL 2015002060A CL 2015002060 A1 CL2015002060 A1 CL 2015002060A1
Authority
CL
Chile
Prior art keywords
compounds
aterosclerosis
pla2
pyrimidinone
imidazo
Prior art date
Application number
CL2015002060A
Other languages
English (en)
Spanish (es)
Inventor
Zehong Wan
Qing Zhang
Yingxia Sang
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50002724&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002060(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CL2015002060A1 publication Critical patent/CL2015002060A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
CL2015002060A 2013-01-25 2015-07-23 Compuestos. CL2015002060A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013070976 2013-01-25
CN2013001556 2013-12-12

Publications (1)

Publication Number Publication Date
CL2015002060A1 true CL2015002060A1 (es) 2015-11-27

Family

ID=50002724

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002060A CL2015002060A1 (es) 2013-01-25 2015-07-23 Compuestos.

Country Status (23)

Country Link
US (1) US9708330B2 (enExample)
EP (1) EP2948452B1 (enExample)
JP (1) JP6306053B2 (enExample)
KR (1) KR20150108897A (enExample)
CN (1) CN105008368B (enExample)
AU (1) AU2014209949B2 (enExample)
BR (1) BR112015017759B1 (enExample)
CA (1) CA2899091A1 (enExample)
CL (1) CL2015002060A1 (enExample)
CR (1) CR20150390A (enExample)
EA (1) EA025885B1 (enExample)
ES (1) ES2642762T3 (enExample)
HK (1) HK1216425A1 (enExample)
IL (1) IL240046A0 (enExample)
MA (1) MA38284B1 (enExample)
MX (1) MX2015009633A (enExample)
PE (1) PE20151251A1 (enExample)
PH (1) PH12015501586A1 (enExample)
SG (1) SG11201505520WA (enExample)
TW (1) TW201443054A (enExample)
UY (1) UY35276A (enExample)
WO (1) WO2014114694A1 (enExample)
ZA (1) ZA201505025B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105008368B (zh) 2013-01-25 2017-02-01 葛兰素史密斯克莱知识产权发展有限公司 基于2,3‑二氢咪唑并[1,2‑c]嘧啶‑5(1H)‑酮的脂蛋白相关磷脂酶A2(Lp‑PLA2)抑制剂
WO2016012916A1 (en) * 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
EP3172211B1 (en) * 2014-07-22 2019-07-03 GlaxoSmithKline Intellectual Property Development Limited Tricyclic imidazo-pyrimidinone derivatives for the treatment of diseases mediated by lp-pla2
WO2016012917A1 (en) * 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN104892459A (zh) * 2015-06-16 2015-09-09 苏州明锐医药科技有限公司 利奥西呱中间体及其制备方法
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
CA3156783A1 (en) * 2019-11-09 2021-05-14 Yun Jin Tricycle dihydroimidazopyrimidone derivative, preparation method thereof, pharmaceutical composition and use thereof
CN111533699B (zh) * 2020-05-27 2023-12-01 龙曦宁（上海）医药科技有限公司 一种2-（三氟甲基）嘧啶-5-醇的合成方法
CN113861220B (zh) * 2020-06-30 2023-06-16 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途
CN113912622B (zh) * 2020-07-10 2023-12-01 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
CN114057740B (zh) * 2021-12-15 2024-04-02 上海赛默罗生物科技有限公司 螺环嘧啶酮衍生物、其制备方法、药物组合物和用途
CN116120329B (zh) * 2022-08-04 2025-05-09 福贝生物医药科技(北京)有限公司 作为Lp-PLA2抑制剂的化合物及其用途
CN116925023B (zh) * 2023-07-18 2025-11-21 江苏桐孚高新材料有限公司 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018035A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
JPH11500415A (ja) 1994-12-22 1999-01-12 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症治療用置換アゼチジン−２−オン
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
CA2225627A1 (en) 1995-07-01 1997-01-23 Deirdre Mary Bernadette Hickey Azetidinone derivatives for the treatment of atherosclerosis
JP2002515728A (ja) 1995-09-29 2002-05-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規用途
JP2000505063A (ja) 1995-12-08 2000-04-25 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のためのアゼチジノン化合物
EP0869943A1 (en) 1995-12-08 1998-10-14 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
IL126696A0 (en) 1996-04-26 1999-08-17 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
JP2001522844A (ja) 1997-11-06 2001-11-20 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ピリミジノン化合物およびそれを含有する医薬組成物
JP2002523402A (ja) 1998-08-21 2002-07-30 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療用ピリミジノン
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
CZ20013904A3 (cs) 1999-05-01 2002-04-17 Smithkline Beecham Plc Pyrimidinonové sloučeniny
GB9910378D0 (en) 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
JP3757703B2 (ja) 1999-09-22 2006-03-22 凸版印刷株式会社 再封可能な開口維持部材付パウチ
HU229479B1 (en) 2000-02-16 2014-01-28 Glaxo Group Ltd Pyrimidine-4-one derivatives
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024807D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119795D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
GB0119793D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127139D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127141D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Plc Novel compounds
GB0127140D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127143D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208279D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP1644353A1 (de) 2003-07-02 2006-04-12 Bayer HealthCare AG Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten
DE102004061009A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
DE102004061008A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one
WO2008048867A2 (en) * 2006-10-13 2008-04-24 Glaxo Group Limited Bicyclic heteroaromatic compounds
US7705005B2 (en) 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
US20080090852A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080090851A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
EP2137158A4 (en) 2007-02-28 2012-04-18 Methylgene Inc LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
WO2008141176A1 (en) 2007-05-11 2008-11-20 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
US20080279846A1 (en) 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
JP2011088847A (ja) 2009-10-21 2011-05-06 Takeda Chem Ind Ltd 三環性化合物およびその用途
WO2012037782A1 (en) * 2010-09-20 2012-03-29 Glaxo Group Limited Tricyclic compounds, preparation methods, and their uses
US8859573B2 (en) * 2010-12-06 2014-10-14 Glaxo Group Limited Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2
EP2651403B1 (en) 2010-12-17 2020-12-02 Glaxo Group Limited Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
CN103827116B (zh) * 2011-07-27 2016-08-31 葛兰素集团有限公司 用作LP-PLA2抑制剂的2,3-二氢咪唑并[1,2-c]嘧啶-5(1H)-酮化合物
KR20140059203A (ko) * 2011-07-27 2014-05-15 글락소 그룹 리미티드 2,3-디히드로이미다조[1,2-c]피리미딘-5(1h)-온 화합물의 lp-pla2 억제제로서의 용도
CN105008368B (zh) 2013-01-25 2017-02-01 葛兰素史密斯克莱知识产权发展有限公司 基于2,3‑二氢咪唑并[1,2‑c]嘧啶‑5(1H)‑酮的脂蛋白相关磷脂酶A2(Lp‑PLA2)抑制剂

Also Published As

Publication number Publication date
UY35276A (es) 2014-08-29
BR112015017759A2 (pt) 2017-07-11
US20150361082A1 (en) 2015-12-17
EP2948452A1 (en) 2015-12-02
CN105008368A (zh) 2015-10-28
JP2016505058A (ja) 2016-02-18
CA2899091A1 (en) 2014-07-31
JP6306053B2 (ja) 2018-04-04
CR20150390A (es) 2015-10-19
WO2014114694A1 (en) 2014-07-31
EA201591379A1 (ru) 2016-01-29
EP2948452B1 (en) 2017-08-09
ZA201505025B (en) 2017-08-30
MA38284B1 (fr) 2018-05-31
US9708330B2 (en) 2017-07-18
HK1216425A1 (zh) 2016-11-11
KR20150108897A (ko) 2015-09-30
BR112015017759B1 (pt) 2022-05-24
CN105008368B (zh) 2017-02-01
TW201443054A (zh) 2014-11-16
PH12015501586A1 (en) 2015-10-05
MX2015009633A (es) 2015-11-30
PE20151251A1 (es) 2015-09-10
AU2014209949A1 (en) 2015-07-30
ES2642762T3 (es) 2017-11-20
EA025885B1 (ru) 2017-02-28
MA38284A1 (fr) 2017-12-29
IL240046A0 (en) 2015-08-31
AU2014209949B2 (en) 2016-09-08
SG11201505520WA (en) 2015-08-28

Similar Documents

Publication Publication Date Title
CL2015002060A1 (es) Compuestos.
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2016001895A1 (es) Compuestos
CL2018000687A1 (es) Nuevos compuestos bicíclicos como inhibidores de atx.
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2014002100A1 (es) Compuestos biciclicos nitrogenados; composicion farmaceutica que los comprende y uso para el tratamiento de la atrofia muscular espinal.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2015002658A1 (es) Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2016001737A1 (es) Derivados heterocíclicos bicíclicos como inhibidores de bromodominio
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
MX395458B (es) Metodos novedosos
BR112015019508A2 (pt) formas sólidas de um inibidor de cdk4/6 seletivo
UY35467A (es) Compuestos orgánicos
CL2014002412A1 (es) Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras.